Goat Polyclonal Fas antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human FAS aa 150-250.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 0.1-0.3 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 3.75 µg/mL | Notes - |
Select an associated product type
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase CASP8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs CASP8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro).
CD95, APT1, FAS1, TNFRSF6, FAS, Tumor necrosis factor receptor superfamily member 6, Apo-1 antigen, Apoptosis-mediating surface antigen FAS, FASLG receptor
Goat Polyclonal Fas antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications. Immunogen corresponding to Synthetic Peptide within Human FAS aa 150-250.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab110021, staining CD95 in Human small intestine tissue by immunohistochemistry.
ab110021, staining CD95 in Human tonsil tissue by immunohistochemistry.
Primary incubation was 1 hour. Detected by chemiluminescence.
All lanes: Western blot - Anti-Fas antibody (ab110021) at 0.1 µg/mL
All lanes: MOLT4 cell lysate (in RIPA buffer) at 35 µg
Predicted band size: 37 kDa
Image collected and cropped by CiteAb under a CC-BY license from the publication
Fas western blot using anti-Fas antibody ab110021. Publication image and figure legend from Huang, W., Bei, L., et al., 2018, Oncotarget, PubMed 29899829.
ab110021 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab110021 please see the product overview.
Fap1-inhibition increased Fas or oxaliplatin induced apoptosis in CD133+ colon cancer cells(A) Fap1-blocking SLV peptide increases Fas-induced apoptosis. Total SW480 or SW620 cells were treated with SLV peptide (or VLS control), with or without Fas-agonist antibody, and analyzed for apoptosis by Annexin V staining. Significant differences indicated by *, **, or *** (p<0.01, n=4 for all comparisons). (B) Fap1-inhibition increases Fas or oxaliplatin induced apoptosis in CD133+ SW620 cells. CD133+ SW620 cells were analyzed for apoptosis by Annexin V staining, with or without Fas-agonist antibody. Some cells were treated with SLV peptide (or VLS control) or transduced with a vector to express Fap1 specific shRNAs (or scrambled control). Significant differences indicated by *, **, ***, or # (p<0.001, n=4 for all comparisons). (C) Fap1-inhibition increases Fas induced caspase 8 cleavage in CD133+ SW620 cells. Cells were analyzed by ELISA for cleavage of caspase 8 (death receptor induced apoptosis). Statistically significant differences indicated by * or ** (p<0.001, n=4). (D) Oxaliplatin treatment increases caspase 9 cleavage in CD133+ SW620 cells. Cells were analyzed by ELISA for cleavage of caspase 9 (intrinsic apoptosis). Statistically significant differences indicated by *, **, ***, or # (p<0.001, n=4). (E) Plasma membrane expression of Fas was not altered by SLV peptide or oxaliplatin treatment of CD133+ SW620 cells. Western blots of cell lysates were probed for Fas or Na+/K+ ATPase (as a loading control). (F) Fap1 inhibition increases Fas or oxaliplatin induced apoptosis in CD133+ SW480 cells. Similar experiments were performed with the SW480 cell line. Statistically significant differences are indicated by * or ** (p<0.001, n=6 for both comparisons).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com